• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Observation of Prostate Cancer Both Effective and Cost-Efficient


In treating low-risk prostate cancer, observation was more effective and less costly than immediate treatment. Optimum management of low-risk prostate cancer remains disputable. MedPage Today reports:

Observation topped initial treatment for low-risk prostate cancer in terms of cost and effectiveness, according to a decision-analysis study.

Both active surveillance and watchful waiting proved more effective and less expensive than immediate treatment. In a comparison of the two observation strategies, watchful waiting added 2 months of quality-adjusted life expectancy and saved $11,000 to $15,000 versus active surveillance, depending on the patient's age.

Initial treatment came out ahead of observation only under circumstances when it reduced prostate cancer mortality by more than 50%, as reported online in Annals of Internal Medicine.

"Using our results, we estimated that if the number of newly diagnosed men with low-risk prostate cancer who selected observation with watchful waiting increased from 10% to 50%, it would result in a cost savings of more than $1 billion," Julia Hayes, MD, of Harvard and Dana-Farber Cancer Institute in Boston, and co-authors concluded. "If one half of the men who chose observation opted for watchful waiting and one half for active surveillance, it would save $500 million.

Read the full story here: http://bit.ly/11Wxkti

Related Videos
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
All rights reserved.